Pipeline

Lung Interaction

How SYGN113 works at the lung mucosal surface

Cilia and mucus help keep bacteria and harmful substances from entering your lungs. In cystic fibrosis (CF), the mucus is thick and viscous, preventing free movement of the cilia, and allowing bacteria colonies to form biofilms and cause chronic inflammation. The modified polysaccharide drug SYGN113 interacts with the native glycoproteins in the mucus and polysaccharides in the biofilms to reduce mucus viscosity, break up biofilms, and provide an anti-inflammatory barrier to promote healing of the lung mucosal surface.

Normal Lung Surface

Cystic Fibrosis Lung Surface

Treated Lung Surface